914 related articles for article (PubMed ID: 27834858)
21. Ursodeoxycholic acid and bile-acid mimetics as therapeutic agents for cholestatic liver diseases: an overview of their mechanisms of action.
Poupon R
Clin Res Hepatol Gastroenterol; 2012 Sep; 36 Suppl 1():S3-12. PubMed ID: 23141891
[TBL] [Abstract][Full Text] [Related]
22. Increased T helper type 17 response to pathogen stimulation in patients with primary sclerosing cholangitis.
Katt J; Schwinge D; Schoknecht T; Quaas A; Sobottka I; Burandt E; Becker C; Neurath MF; Lohse AW; Herkel J; Schramm C
Hepatology; 2013 Sep; 58(3):1084-93. PubMed ID: 23564624
[TBL] [Abstract][Full Text] [Related]
23. Bile duct bacterial isolates in primary sclerosing cholangitis: a study of explanted livers.
Olsson R; Björnsson E; Bäckman L; Friman S; Höckerstedt K; Kaijser B; Olausson M
J Hepatol; 1998 Mar; 28(3):426-32. PubMed ID: 9551680
[TBL] [Abstract][Full Text] [Related]
24. A case of coexisting primary biliary cirrhosis and primary sclerosing cholangitis: a new overlap of autoimmune liver diseases.
Burak KW; Urbanski SJ; Swain MG
Dig Dis Sci; 2001 Sep; 46(9):2043-7. PubMed ID: 11575461
[TBL] [Abstract][Full Text] [Related]
25. Selected Aspects of the Intricate Background of Immune-Related Cholangiopathies-A Critical Overview.
Kasztelan-Szczerbinska B; Rycyk-Bojarzynska A; Szczerbinska A; Cichoz-Lach H
Nutrients; 2023 Feb; 15(3):. PubMed ID: 36771465
[TBL] [Abstract][Full Text] [Related]
26. Lack of concomitant expression of ICAM-1 and HLA-DR on bile duct cells from patients with primary sclerosing cholangitis and primary biliary cirrhosis.
Broomé U; Hultcrantz R; Scheynius A
Scand J Gastroenterol; 1993 Feb; 28(2):126-30. PubMed ID: 8095102
[TBL] [Abstract][Full Text] [Related]
27. The gut-liver axis in cholangiopathies: focus on bile acid based pharmacological treatment.
Cariello M; Gadaleta RM; Moschetta A
Curr Opin Gastroenterol; 2022 Mar; 38(2):136-143. PubMed ID: 35034082
[TBL] [Abstract][Full Text] [Related]
28. Alterations in tight junctions differ between primary biliary cirrhosis and primary sclerosing cholangitis.
Sakisaka S; Kawaguchi T; Taniguchi E; Hanada S; Sasatomi K; Koga H; Harada M; Kimura R; Sata M; Sawada N; Mori M; Todo S; Kurohiji T
Hepatology; 2001 Jun; 33(6):1460-8. PubMed ID: 11391535
[TBL] [Abstract][Full Text] [Related]
29. The role of Helicobacter spp. in the pathogenesis of primary biliary cirrhosis and primary sclerosing cholangitis.
Boomkens SY; de Rave S; Pot RG; Egberink HF; Penning LC; Rothuizen J; Zondervan PE; Kusters JG
FEMS Immunol Med Microbiol; 2005 May; 44(2):221-5. PubMed ID: 15866219
[TBL] [Abstract][Full Text] [Related]
30. [Cholestatic liver diseases].
Thimme R; Opitz OG; Blum HE; Kreisel W
Ther Umsch; 2004 Aug; 61(8):521-7. PubMed ID: 15457969
[TBL] [Abstract][Full Text] [Related]
31. Exploring Advanced Therapies for Primary Biliary Cholangitis: Insights from the Gut Microbiota-Bile Acid-Immunity Network.
Guo Z; He K; Pang K; Yang D; Lyu C; Xu H; Wu D
Int J Mol Sci; 2024 Apr; 25(8):. PubMed ID: 38673905
[TBL] [Abstract][Full Text] [Related]
32. New Therapeutic Strategies for Primary Sclerosing Cholangitis.
Williamson KD; Chapman RW
Semin Liver Dis; 2016 Feb; 36(1):5-14. PubMed ID: 26870928
[TBL] [Abstract][Full Text] [Related]
33. New insights into autoimmune cholangitis through animal models.
Trauner M; Fickert P; Baghdasaryan A; Claudel T; Halilbasic E; Moustafa T; Wagner M; Zollner G
Dig Dis; 2010; 28(1):99-104. PubMed ID: 20460897
[TBL] [Abstract][Full Text] [Related]
34. Autoimmune liver disease, autoimmunity and liver transplantation.
Carbone M; Neuberger JM
J Hepatol; 2014 Jan; 60(1):210-23. PubMed ID: 24084655
[TBL] [Abstract][Full Text] [Related]
35. Identification of beta-subunit of bacterial RNA-polymerase--a non-species-specific bacterial protein--as target of antibodies in primary biliary cirrhosis.
Roesler KW; Schmider W; Kist M; Batsford S; Schiltz E; Oelke M; Tuczek A; Dettenborn T; Behringer D; Kreisel W
Dig Dis Sci; 2003 Mar; 48(3):561-9. PubMed ID: 12757171
[TBL] [Abstract][Full Text] [Related]
36. Antineutrophil nuclear antibodies (ANNA) in primary biliary cirrhosis: their prevalence and antigen specificity.
Orth T; Gerken G; Meyer Zum Büschenfelde KH; Mayet WJ
Z Gastroenterol; 1997 Feb; 35(2):113-21. PubMed ID: 9066101
[TBL] [Abstract][Full Text] [Related]
37. Loss of apical sodium bile acid transporter alters bile acid circulation and reduces biliary damage in cholangitis.
Meadows V; Marakovits C; Ekser B; Kundu D; Zhou T; Kyritsi K; Pham L; Chen L; Kennedy L; Ceci L; Wu N; Carpino G; Zhang W; Isidan A; Meyer A; Owen T; Gaudio E; Onori P; Alpini G; Francis H
Am J Physiol Gastrointest Liver Physiol; 2023 Jan; 324(1):G60-G77. PubMed ID: 36410025
[TBL] [Abstract][Full Text] [Related]
38. [Autoimmune hepatitis and overlap syndrome: diagnosis].
Berg PA; Klein R
Praxis (Bern 1994); 2002 Aug; 91(34):1339-46. PubMed ID: 12233264
[TBL] [Abstract][Full Text] [Related]
39. Bile microbiota in primary sclerosing cholangitis: Impact on disease progression and development of biliary dysplasia.
Pereira P; Aho V; Arola J; Boyd S; Jokelainen K; Paulin L; Auvinen P; Färkkilä M
PLoS One; 2017; 12(8):e0182924. PubMed ID: 28796833
[TBL] [Abstract][Full Text] [Related]
40. Treatment of primary sclerosing cholangitis.
Floreani A; De Martin S
Dig Liver Dis; 2021 Dec; 53(12):1531-1538. PubMed ID: 34011480
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
